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ABSTRACT 
A total of 42 patients who had failed prior renal transplantation underwent repeat cadaveric 
transplantation using cyclosporin A and low dose steroid immunosuppression. Patient survival at 1 
year was 100 per cent. Over-all graft survival was 83 per cent at 1 year, which was significantly 
better than had been obtainable previously in this high risk group. Repeat cadaver transplantation 
with cyclosporin A is safe and offers those who have failed previous transplantation an opportunity 
for existence free of dialysis. 
Patients undergoing repeat renal transplantation after fail-
ure of a first kidney transplant are at high risk for graft failure. 
Cyc1osporin A is a new, potent immunosuppressant that has 
been shown to be superior to conventional immunosuppression 
with azathioprine and predisone in early clinical trials. l -3 From 
March 1981 to March 1982 all patients undergoing repeat 
kidney transplantation were managed with a regimen of cy-
c1osporin A and low doses of steroids to determine if the 
beneficial effects of this new agent could be extended to this 
high risk group. 
MATERIALS AND METHODS 
From March 1981 to March 1982, 42 patients underwent 
repeat cadaver kidney transplantation. Of these patients 34 
had received 1, 6 had received 2 and 2 had received 3 prior 
cadaver transplants, and 27 had lost the previous transplant in 
<12 months. HLA (A and B loci) and DR matching were 
random between donor and recipient, and averaged 1.3 (A and 
B loci). Average patient age was 33 years, with a range of 9 to 
61 years. Ten patients had antibodies reactive against >70 per 
cent lymphocytes from a panel of 50 random donors at the time 
of transplantation, including 4 who had antibodies against 99 
per cent of all lymphocyte panel donors on current and all 
historical sera. Two patients had nonconcurrent sera that killed 
kidney donor lymphocytes (T and B cells at 4C and 37C, 
respectively). Current sera for crossmatch were negative in all 
patients. Complete blood transfusion histories were available 
on 39 of the 42 patients who underv .. ent transplantation with 
cyclosporin A and 16 of 22 with azathioprine immunosuppres-
sion. Of 39 patients who received cyclosporin A 37 had had ~P 
whole blood transfusions before traIL9)lantation, compared to 
14 of 16 who received azathioprine. 
Immune suppression consisted of 17.5 mg./kg. oral cyclos-
porin A 5 hours before transplantation and daily thereafter for 
the first 1 to 2 months. The dosage w~ tapered to 8 to 12 mg./ 
kg. depending on the serum creatinin£:. Methylprednisolone (1 
gm.) was given intravenously before transplantation. Predni-
sone was tapered from 200 to 20 mg. daily during the first 5 
days after transplantation. Rejection lras diagnosed clinically 
on the basis of 2 consecutive daily creatinine increases of >1 
mg. per cent with no other demonstrcab:e cause of reduced renal 
function, and was treated by recycl£: of prednison£: to 200 mg. 
daily, tapered during 5 days to 20 n:g. daily. Followup ranged 
from 12 to 22 months, with a mean o! 14 months. 
Accepted Cor publication July 1, 1983. 
17 
RESULTS 
Figure 1 shows the actual I-year graft survival rates for the 
entire group compared to historical controls, with over-all graft 
survival rates of 83 per cent versus 36 per cent in the historical 
controls (p = 0.005). There have been no deaths. However, 7 
kidneys were lost during followup; 6 from rejection and 1 from 
an arterial thrombosis. Of the 6 patients who lost the kidney 
because of rejection 3 had reactive antibodies against 99 per 
cent lymphocyte donors (preformed reactive antibodies) and 
the remaining 3 were complete HLA mismatches. Graft survival 
in recipients with a prior graft survival of >12 months was 
compared to that in recipients with a prior graft survival <12 
months and was not significantly different (fig. 2). 
DISCUSSION 
Previous studies of repeat cadaver kidney transplantation 
have shown I-year graft survival rates of 40 to 50 per cent.4.& 
Our I-year graft survival for repeat cadaver kidney transplants 
in the 21h years prior to this study was 36 per cent. Our patients 
were not randomized because of the previous poor graft failure 
with azathioprine and prednisone, and because of the early 
results of improved graft survival in patients with primary 
cadaveric transplants using cyclosporin A. The over-all graft 
survival of 83 per cent with no patient deaths is significantly 
better than historic controls at our institution. Patients who 
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FIG. 1. Graft survival with CYCl08porin versus azathioprine 
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FtG. 2. Graft survival as function of time to previous graft loss 
lost previous grafts quickly had a lower graft survival than 
those whose previous graft loss was > 12 months irrespective of 
the cause of loss. However, if those patients who lost kidneys 
in <12 months who also had 99 per cent preformed reactive 
antibodies are excluded there is little difference in graft survival 
(about 90 per cent in patients who lost the previous kidney in 
> 12 and <12 months). This finding is similar to that obtainable 
in patients who underwent primary cadaver transplantation 
with cyclosporin A.6 
Others have demonstrated the efficacy of cyclosporin A in 
high risk patients.7.8 Cyclosporin A nephrotoxicity and its 
management have been discussed previously.9 Nephrotoxicity 
has not resulted in any recognized graft loss in our patients. 
High responding patients are a large part of most cadaver 
transplant lists with high levels of preformed antibodies, in 
whom it is difficult to achieve a negative lymphocyte cross-
match against donor kidneys. In the 10 patients with preformed 
reactive antibodies >70 per cent who received cyclosporin A 
and prednisone the graft survival was 5 (50 per cent), which is 
comparable to those who received conventional immuno-
suppression but less than the 90 per cent graft survival that 
has been observed using cyclosporin A. Humoral rejection may 
have been important, since 4 of the 6 patients who lost the 
grafts owing to rejection did so in an accelerated fashion 1 week 
after transplantation. Control of this form of rejection may 
require additional treatments, such as thoracic duct drainage 
or plasmapheresis, if this especially troublesome group of pa-
tients can undergo transplantation. The use of cyclosporin A 
and low dose steroid has improved early graft survival in 
patients who had failed previous renal transplants. 
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EDITORIAL COMMENTS 
CycIosporin A has been shown to be more effective than azathioprine 
in preventing renal allograft rejection and, as indicated by the authors, 
first cadaver graft survival improved markedly with this agent. The 
authors now report a similar improvement in graft survival in repeat 
cadaver graft recipients. They rightly have not performed this study in 
a prospective randomized trial because of the marked improvement in 
outcome with cyclosporin A when compared to historical controls. If 
the few patients in their study who had high levels of preformed 
antibody are excluded from the calculation, then the results achieved 
with second cadaver grafts is almost the same as that achieved with 
first cadaver grafts. Cyclosporin A is without doubt an important new 
addition to the immunosuppression regimen of transplant recipients. 
The authors are to be commended for helping to define better the role 
of this potent new agent in renal transplantation. 
RusseU K Lawson 
Department of Urology 
Medical College of Wisconsin 
Milwaukee, Wisconsin 
Cyclosporin A is a remarkably potent immunosuppressive drug 
whose advent had led deservedly to enhanced expectations in renal 
transplantation. Nevertheless, the most appropriate manner for its use 
in defined clinical settings has not yet been resolved. Although substi· 
tution of cyclosporin A for azathioprine has yielded excellent results in 
flrSt renal transplants, recent studies suggest that it may be possible to 
achieve comparable graft survival rates with existing immunosuppres-
sive regimens that incorporate antilymphocyte globulin!' 2 However, in 
re·transplantation, even with adjunctive antilymphocyte globulin, graft 
survival has been extremely poor when the duration of initial graft 
function was <12 months (reference 4 in article). This report demon-
strates that excellent results can be obtained when patients in this 
immunologically high risk subgroup are managed with cycIcsporin A. 
This is an important contribution toward elucidating the most useful 
applications of this new agent in renal transplantation. 
Andrew C. Novick 
Department of Urology 
Cleveland Clinic Foundation 
Cleveland, Ohio 
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